

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Canceled)

2. (Currently Amended) ~~A pharmaceutical~~An immunogenic composition comprising a liposome formulated with at least one polypeptide, wherein the at least one polypeptide comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO : 2, wherein the liposome comprises a bacterial phospholipid selected from *E. coli*, *N. meningitidis*, and *N. lactamica*, and wherein the ~~composition~~at least one polypeptide is capable of ~~inducing an immune response against *Neisseria meningitidis* eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2.~~

3. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition according to claim 2, wherein the at least one polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO : 2.

4. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition according to claim 2, wherein the at least one polypeptide comprises the amino acid sequence set forth in SEQ ID NO : 2.

5. (Currently Amended) ~~A pharmaceutical~~An immunogenic composition comprising a liposome formulated with a polypeptide comprising an immunogenic fragment of at least 10 contiguous amino acids of SEQ ID NO : 2, wherein the liposome comprises a bacterial phospholipid selected from *E. coli*, *N. meningitidis*, and *N. lactamica*, and wherein the

~~composition polypeptide is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2 inducing an immune response against *Neisseria meningitidis*.~~

6. (Canceled)

7. (Currently Amended) The ~~pharmaceutical~~ immunogenic composition according to claim 2, wherein said at least one isolated polypeptide is selected from:

a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2 wherein the N-terminal methionine at residue 1 is deleted; and

a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, wherein the secretory amino acid sequence is deleted.

8. –10. (Canceled)

11. (Currently Amended) ~~A pharmaceutical~~ An immunogenic composition comprising a liposome formulated with a chimeric polypeptide that comprises two or more immunogenic fragments of a polypeptide, which polypeptide consists of the amino acid sequence set forth in SEQ ID NO:2, wherein each immunogenic fragment comprises at least 10 contiguous amino acids of SEQ ID NO:2, and wherein the two or more immunogenic fragments are linked to form the chimeric polypeptide, wherein the liposome is a bacterial phospholipid selected from *E. coli*, *N. meningitidis*, and *N. lactamica*, and wherein said ~~composition~~ chimeric polypeptide is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2 inducing an immune response against *Neisseria meningitidis*.

12. (Currently Amended) The ~~pharmaceutical~~ immunogenic composition according to claim 2, wherein the composition comprises at least two polypeptides wherein each of the at least two polypeptides comprises an amino acid sequence at least 90% identical to the

amino acid sequence set forth in SEQ ID NO : 2, and wherein the at least two polypeptides are linked to form a chimeric polypeptide.

13. – 16. (Canceled)

17. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition according to claim 2, wherein said liposome further comprises at least one adjuvant selected from Lipid A, monophosphoryl lipid A (MPLA), a lipopolysaccharide, and a cytokine.

18. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition according to claim 2, wherein said liposome further comprises 0 to 25% cholesterol.

19. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition according to any one of claims 2, 5, and 11, wherein said composition further comprises a pharmaceutically acceptable adjuvant.

20. (Currently Amended) A method for inducing an immune response against *N. meningitidis* in a host wherein the immune response comprises eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2, said method comprising administering to said host an effective amount of the ~~pharmaceutical-immunogenic~~ composition according to any one of claims 2, 5, and 11 to elicit the immune response.

21. – 23. (Canceled)

24. (Previously Presented) The method according to claim 20, wherein said host is a mammal.

25. (Previously Presented) The method according to claim 24, wherein said mammal is a human.

26. (Previously Presented) The method according to claim 25, wherein said human is an adult human.

27. (Currently Amended) The method according to claim 20 wherein the ~~pharmaceutical-immunogenic~~ composition is administered in unit dosage form of about 0.001 to 100 µg/kg (polypeptide weight/body weight) with an interval of about 1 to 6 weeks between immunizations.

28.-33. (Canceled)

34. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition according to any one of claims ~~2-5, 7, 11, and 12,~~ 2-4 and 7 wherein ~~said-said at least one~~ polypeptide is capable of eliciting antibodies that are bactericidal.

35. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition according to any one of claims 2-5, 7, 11, and 12,

wherein the composition is capable of eliciting antibodies that bind to *N. meningitidis* of any one of serogroup A, B, and C.

36. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition according to claim 5 wherein the immunogenic fragment comprises contiguous amino acids 108-125 of SEQ ID NO:2.

37. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition of claim 36 wherein the composition further comprises a second immunogenic fragment, said second immunogenic fragment comprising contiguous amino acids 68-80 of SEQ ID NO:2.

38. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition of claim 11 wherein one of the two or more immunogenic fragments comprises contiguous amino acids 108-125 of SEQ ID NO:2.

39. (Currently Amended) The ~~pharmaceutical-immunogenic~~ composition of claim 11 wherein one of the two or more immunogenic fragments comprises contiguous amino acids 108-125 of SEQ ID NO:2 and one immunogenic fragment comprises contiguous amino acids 68-80 of SEQ ID NO:2.

40. (New) The immunogenic composition according to claim 5 wherein the polypeptide is capable of eliciting antibodies that are bactericidal.

41. (New) The immunogenic composition according to claim 11 wherein the chimeric polypeptide is capable of eliciting antibodies that are bactericidal.

42. (New) The immunogenic composition according to claim 12 wherein each of the at least two polypeptides is capable of eliciting antibodies that are bactericidal.

43. (New) The immunogenic composition according to claim 2 wherein the at least one polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO : 2 comprises contiguous amino acid residues 68-80 of SEQ ID NO:2.

44. (New) The immunogenic composition according to claim 2 wherein the at least one polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO : 2 comprises contiguous amino acid residues 108-125 of SEQ ID NO:2.

45. (New) The immunogenic composition according to claim 2 wherein the at least one polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO : 2 comprises contiguous amino acid residues 68-80 and contiguous amino acid residues 108-125 of SEQ ID NO:2.